Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the milan criteria in transplantable hepatocellular carcinoma: A retrospective analysis based on tissue microarrays

Liver Transplantation

Volumn 19, Issue 3, 2013, Pages 336-345

  Shim, Ju Hyun ^a   Lee, Han Chu ^a   Han, Seungbong ^a   Kang, Hyo Jeong ^a   Yu, Eunsil ^a   Lee, Sung Gyu ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 1BETA;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84875164246     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23584     Document Type: Article

References (26)

1. Hwang S, Lee SG, Belghiti J,. Liver transplantation for HCC: its role: Eastern and Western perspectives. J Hepatobiliary Pancreat Sci 2010; 17: 443-448.
2. Bruix J, Sherman M,; for American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
3. Lee S, Ahn C, Ha T, Moon D, Choi K, Song G, et al. Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Sci 2010; 17: 539-547.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
5. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW,. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143: 182-188.
6. Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K, et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl 2004; 10: 1343-1354.
7. Cescon M, Ravaioli M, Grazi GL, Ercolani G, Cucchetti A, Bertuzzo V, et al. Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. J Transplant 2010; 2010: 904152.
8. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-137.
9. Bois-Joyeux B, Danan JL,. Members of the CAAT/enhancer-binding protein, hepatocyte nuclear factor-1 and nuclear factor-1 families can differentially modulate the activities of the rat alpha-fetoprotein promoter and enhancer. Biochem J 1994; 301 (pt 1): 49-55.
10. Lazarevich NL,. Molecular mechanisms of alpha-fetoprotein gene expression. Biochemistry (Mosc) 2000; 65: 117-133.
11. Ninomiya T, Hayashi Y, Saijoh K, Ohta K, Yoon S, Nakabayashi H, et al. Expression ratio of hepatocyte nuclear factor-1 to variant hepatocyte nuclear factor-1 in differentiation of hepatocellular carcinoma and hepatoblastoma. J Hepatol 1996; 25: 445-453.
12. Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, et al. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 2004; 39: 1038-1047.
13. Zeng X, Lin Y, Yin C, Zhang X, Ning BF, Zhang Q, et al. Recombinant adenovirus carrying the hepatocyte nuclear factor-1alpha gene inhibits hepatocellular carcinoma xenograft growth in mice. Hepatology 2011; 54: 2036-2047.
14. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008; 14: 935-945.
15. Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, et al. Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation. J Gastrointest Surg 2011; 15: 971-981.
16. Lyu J, Lee SG, Hwang S, Lee SO, Cho OH, Chae EJ, et al. Chest computed tomography is more likely to show latent tuberculosis foci than simple chest radiography in liver transplant candidates. Liver Transpl 2011; 17: 963-968.
17. Ryu SH, Chung YH, Lee H, Kim JA, Shin HD, Min HJ, et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology 2008; 47: 929-936.
18. Lau B, Cole SR, Gange SJ,. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009; 170: 244-256.
19. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS,. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
20. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
21. Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR,. Systematic review: the prognostic role of alpha-fetoprotein following liver transplant for hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35: 987-999.
22. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M,. Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 2011; 17 (suppl 2): S72-S80.
23. Fujioka M, Nakashima Y, Nakashima O, Kojiro M,. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 2001; 34: 1128-1134.
24. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, Uemoto S,. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009; 9: 2362-2371.
25. Hellerbrand C, Amann T, Schlegel J, Wild P, Bataille F, Spruss T, et al. The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma. Gut 2008; 57: 243-251.
26. Xu L, Hui L, Wang S, Gong J, Jin Y, Wang Y, et al. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res 2001; 61: 3176-3181.